Kidney cancer scan study pulled before it even started

NCT ID NCT07084909

Terminated Diagnosis Sponsor: Lantheus Medical Imaging Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if a special PET/CT scan using a radioactive tracer called piflufolastat F 18 could better detect whether clear cell renal cell carcinoma (a type of kidney cancer) has spread. Researchers planned to enroll adults with suspected or high-risk metastatic disease. However, the study was withdrawn before any participants were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: piflufolastat F 18 (a radioactive tracer used in PET/CT scans)
What this could lead to: If successful, this imaging method could help doctors more accurately detect if kidney cancer has spread, guiding better treatment decisions.
What could go wrong: The study was withdrawn before any participants enrolled, so no results are available. It is unclear if the approach would work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA

Contacts and locations

Locations

Washington University in St. Louis

St Louis, Missouri, 63130, United States
XCancer

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.